Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity

Mohyeddin Assali, a,b Naim Kittana, b Sahar Alhaj Qasem, a Raghad Adas, a Doaa Saleh, a Asala Arara and Osayd Zohud b

Cancer is a major worldwide health problem, for which chemotherapy is a common treatment option. However, drug toxicity and the development of resistance to chemotherapy are two main challenges associated with the traditional anticancer drugs. Combined pharmacological therapy based on different mechanisms might be an effective strategy in cancer treatment, and could exhibit a synergistic therapeutic efficacy. Herein, we aim to combine combretastatin A4 (CA4) and camptothecin (Cpt) chemically into a codrug through two hydrophilic linkers utilizing click chemistry to improve their water solubility and anticancer activity. The synthesized amphiphilic structure could self-assemble into a micelle structure as confirmed by atomic force microscopy (AFM) and dynamic light scattering (DLS), which showed a high stability and improved water solubility at pH 7.4, with a low critical micelle concentration (CMC) value of 0.9 mM. Moreover, in vitro hydrolysis was observed upon incubation of the hybrid compound with an esterase enzyme, which suggested a complete disassembly into the starting active drugs. Finally, cytotoxicity studies on HeLa cancer cells showed that the codrug demonstrated an enhanced (five fold) cytotoxicity as compared with the free drugs. In addition the combination index (CI) was <1, which suggests a synergistic activity for the codrug. Moreover, the tested concentrations of the codrug were not significantly cytotoxic to a noncancerous fibroblast cell line. The imaging of HeLa cells treated with FITC-loaded micelles showed a rapid internalization. In conclusion, the codrug of CA4 and Cpt might be a potential novel anticancer drug as it demonstrated a synergistic cytotoxic activity that might spare noncancerous cells.

1. Introduction

Cancer is considered one of the complicated diseases that presents as a major leading cause of death worldwide. Cancer chemotherapy is among one of the major treatment options for cancer, besides surgery and radiotherapy when applicable. Chemotherapy can be used as a supplemental treatment to attack micro-metastases following surgery and radiation. It can also be given prior to the surgical procedure in order to shrink the tumor. Anticancer drugs are normally administered systemically, so that they distribute throughout the body tissues and may affect not only the cancerous cells but also many normal cells leading to various side effects on the heart, kidneys, bladder, digestive system, bone marrow, lungs and many others. Drug toxicity and the development of drug resistance are among the main challenges associated with the use of traditional anticancer drugs. Toxicity can cause life-threatening consequences that may require the cessation of the treatment. On the other hand, the development of drug resistance by tumors might be a reason for the treatment failure in many cases. Therefore, there is a great demand to develop a new strategy to fight this lethal disease. The combination of multiple drugs with various mechanisms could be an effective strategy that might exhibit a synergistic activity. However, the proper delivery of the combined therapy has some limitations and a proper chemical combination is highly desired due to the various physiological barriers and enzymatic processes in the body.

Combretastatin A4 (CA4) and camptothecin (Cpt) are among many clinically used anticancer drugs. CA4 is a natural compound that is extracted from an African willow tree called Combretum caffrum. It acts as a vascular disrupting agent (VDA). In addition it can inhibit the polymerization of tubulin resulting in cell death. However, it has two major disadvantages; the low water solubility and the short half life. On the other hand, Cpt is extracted from a Chinese plant called Camptotheca acuminata. It inhibits topoisoerase I enzyme, which is important in the DNA replication, resulting in cell death. Similar to CA4, Cpt also suffers from low water solubility, but in addition it has low stability and preponderance of a less active carboxylate form at physiologic pH.
Solid tumors unendingly grow in size. In many times this increase in tumor size is not only associated with an increase in tumor tissue hypoxia, but also a reduction in tumor blood flow and consequently an impairment in the delivery of the chemotherapeutic agents. However, some research studies suggested that VDAs could otherwise be superior against such large tumors, because tumor vasculature could be already susceptible to occlusion due to elevated interstitial fluid pressure, which are more associated with advanced tumor masses. Moreover a recent review study demonstrated that combining VDAs with traditional chemotherapeutic agents has greater potential to eradicate tumor cells.

Herein we aim to combine the VDA agent (CA4) with the topoisomerase I inhibitor (Cpt) chemically for the first time using a suitable hydrophilic linkers of tetraethylene glycol that would permit the formation of an amphiphilic structure that could assemble into micelles, which might in turn improve the water solubility of the resulting molecules and provide a synergistic effect of the combined therapy (Scheme 1).

2. Experimental

2.1. Reagents and instruments

All chemical materials that used in the experiments were of analytical grade and were purchased from commercial suppliers. Tetraethylene glycol, L-ascorbic acid sodium salt 99%, quinoline, propargyl bromide, succinic anhydride, copper, anhydrous diethylether (DMAP) was purchased from Merck Company. Esterase from (Alfa Aesar Company, England). 4-(Dimethylamino) pyridine (EDC), 2-(3,4,5-trimethoxyphenyl) acetic acid, 3-hydroxy-4-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (99%, quinoline, propargyl bromide, succinic anhydride 99%, 1-fluorocinnamic acid, 99%, N,N-diisopropylethylamine (DIPEA), Boc anhydride, 98%, thionyl chloride 99%, triethylamine, L-glutamine and penicillin/streptomycin were purchased from Promega (Wisconsin, USA).

2.2. Synthesis

The following compounds were synthesized and characterized according to our previous reported study: OH-TEG-OTS (1), OH-TEG-N1 (2), COOH-TEG-N3 (3), CA4 (4) and CA4-TEG-N1 (5).

2.2.1. Synthesis of OH-TEG-alkyne (6).

A solution of NaH (247 mg, 10.3 mmol) dissolved in 5 ml THF was added dropwise over 30 min to a solution of tetraethylene glycol (1.0 g, 5.15 mmol) in anhydrous DCM (212.0 mg, 0.86 mmol), Cpt (100 mg, 0.29 mmol), EDC (211 mg, 1.16 mmol) and DMAP (106 mg, 0.86 mmol) in anhydrous DCM. The following compounds were synthesized and characterized according to our previous reported study: OH-TEG-ONS (1), OH-TEG-N1 (2), COOH-TEG-N3 (3), CA4 (4) and CA4-TEG-N1 (5).
of each CA4 and Cpt was prepared (conc. 0.5 mg ml⁻¹), then, it was diluted to a series of concentrations and the absorbance was measured by spectrophotometer at λ max 290 nm for CA4, 365 nm for Cpt and 420 nm for codrug 9.

2.3.2. Preparation of buffer solutions. Acetate buffer solution pH 4.5 : 14 ml of 2 M acetic acid was added to 2.99 g of sodium acetate dissolved in water and diluted to 1000 ml with water.

Phosphate buffer solution pH 7.4 : 250.0 ml of 0.2 M potassium dihydrogen phosphate was added to 393.4 ml of 0.1 M sodium hydroxide.

Carbonate buffer solution pH 9.2 : 0.1 M sodium carbonate was prepared by dissolving 1.06 g anhydrous Na₂CO₃ in water and diluted to 100 ml and 0.1 M sodium bicarbonate was prepared by dissolving 0.84 g NaHCO₃ in water and diluted to 100 ml. Then, 90 ml of diluted sodium bicarbonate were added to 10 ml of diluted sodium carbonate in to 100 ml volumetric flask.

2.3.3. Solubility study. The solubility of the synthesized codrug 9 was determined by using shake-flask technique as reported. Briefly, compound 9 was added in excess to 1.5 ml Eppendorf tube containing 500 μl of phosphate buffer (pH 7.4). The tube was placed onto a plate shaker at 300 rpm, 37 °C. Sampling was performed after 24, 48 and 72 h. The excess solid was separated from the solution by centrifugation at 15 000 rpm for 10 min. After that, exactly 100 μl of the supernatant was taken and diluted. Then, the absorbance was measured at λ_max 420 nm and concentrations were obtained using calibration curve with correlation coefficient more than 0.99. The intrinsic solubility represented by steady-state concentrations.

2.3.4. CMC determination. The critical micelle concentration (CMC) of codrug 9 was determined by using pyrene as fluorescent probe. Briefly, different concentrations ranging from 0.05 to 5 × 10⁻⁶ mg ml⁻¹ of codrug 9 were added to a saturated solution of pyrene (6 × 10⁻⁷ M). The flasks were then heated for 2 h at 60 °C with shaking to equilibrate the pyrene and the micelles. Subsequently the flasks were allowed to cool down over night to room temperature. The fluorescence excitation spectra were obtained with an emission wavelength of 390 nm. The CMC was determined as the intersection when extrapolating the intensity ratios of I₃₃₃/I₃₇₃ for low and high concentration regions.

2.3.5. Stability study. The stability study was determined on three different pHs (4.5, 7.4, 9.2). Three stocks of concentration 1.0 mg ml⁻¹ were prepared in the three different prepared buffers and aliquots were withdrawn during one week and analyzed at UV spectrophotometer.
The absorbance of the collected samples was measured by UV spectrophotometer.

2.5. Cytotoxicity study

2.5.1. Cell lines. The cytotoxic activity of the test compounds was studied on HeLa cancer cells and 3T3 fibroblasts.

2.5.2. Cell culture. HeLa cells and 3T3 fibroblasts were cultured in 15 cm² plastic culture plate in culture growth medium (CGM) which consists of DMEM medium supplemented with 10% fetal bovine serum (FBS), L-glutamine and penicillin/streptomycin. Cells were maintained in the above medium at 37 °C in a humidified atmosphere containing 5% CO₂.

2.5.3. Cell viability study. HeLa cells and 3T3 fibroblasts were cultured in 96-well plates. They were incubated with 100 µl per well CGM supplemented with different concentrations of the test compounds for 48 h. Then, they were incubated for 1 h at 37 °C and 5% CO₂ with 20 µl per well of MTS reagent. Finally, the absorbance was measured by a plate reader at a wavelength of 490 nm. In order to confirm the synergism, Chou and Talalay’s method was followed using CompuSyn software to calculate the LD₅₀, combination index (CI) and the dose reduction index (DRI), so that the CI = 1 indicates additive effect, while CI < 1 indicates synergistic activity and CI > 1 indicates antagonism activity.

2.5.4. Cellular uptake study. The cellular uptake of codrug 9 was studied by loading the fluorescent dye fluorescein isothiocyanate (FITC) into the micelles of codrug 9. 1 mg of FITC was added to a stock solution of codrug 9 that was previously prepared as 0.5 mg ml⁻¹ of DMEM medium. The solution was then sonicated for 30 min. After that it was centrifuged at 5000 rpm for 10 min in order to remove the unloaded FITC. Subsequently 100 µl aliquots of the resulting FITC-loaded micelles were diluted with 500 µl DMEM and were then added to HeLa cells cultured in 24-well plates. The cells were imaged by fluorescent microscope (Olympus IX73®) after 1 and 2 h of incubation; before imaging the medium was discarded, and the cells were washed several times with PBS.

3. Results and discussion

3.1. Synthesis

The synthesis was achieved by using the adequate linkers to provide the correct hydrophobic/hydrophilic balance in order to improve their water solubility, therefore, we utilized two derivatives of tetraethylene glycol one for the Cpt and other for the CA4 since the biocompatible polyethylene glycol (PEG) chain has shown effective improvement in the solubility of hydrophobic anticancer drugs conjugate and the prolong circulation of the formed micelles.

The first linker was synthesized through selective monosylation of tetraethylene glycol followed by nucleophilic substitution with sodium azide to obtain compound 2 and terminated by oxidation reaction utilizing Jones reagent to obtain the bifunctional linker 3. In a final step, an esterification reaction with CA4 to obtain CA4-TEG-N₃ 5 as shown in Scheme 2.

Once the first moiety has successfully synthesized, the second linker was prepared by reacting tetraethylene glycol selectively with propargyl bromide in the presence of sodium hydride in THF. Followed by oxidation reaction to obtain compound 7 that reacts with Cpt through esterification reaction using EDC as a coupling agent and DMAP to obtain Cpt-TEG alkyne 8 as shown in Scheme 3.

As the two moieties were successfully synthesized CA4-TEG-N₃ 5 and Cpt-TEG-alkyne 8, they were connected through click reaction, which is occurred in one pot and produced a high yield reaction with a minimum byproduct. Herein we used anhydrous CuSO₄ in the presence of ascorbic acid dissolved in a mixture DCM : H₂O to synthesized CA4-TEG-triazole-TEG-Cpt 9 as shown in the Scheme 4. The connection between the two anticancer drugs was through triazole group that are highly enzymatic and chemically stable. Moreover, the direct linkage between the CA4, Cpt and linkers was through an ester bond that can be hydrolyzed easily by esterase enzyme that is usually

---

Scheme 2 Synthetic scheme of CA4-TEG-N₃ 5.

Scheme 3 Synthetic scheme of Cpt-TEG-Alkyne 8.

Scheme 4 Synthetic scheme of CA4-TEG-triazole-TEG-Cpt 9 (codrug 9).
overexpressed in cancer cells with a high intracellular concentration\textsuperscript{39,40} in order to give a rapid release profile of the anticancer drugs.

3.2. Solubility, stability and micelle formation

In order to investigate whether the conjugation of the two low-water-soluble drugs with the hydrophilic linkers could improve the overall aqueous solubility, the shake-flask method was implemented to study the solubility of codrug 9 at 37 °C in sodium phosphate buffer (pH 7.4). The test was performed based on calibration curves constructed by UV-Vis spectrophotometry. The solubility test was performed in triplicates. The results showed an improvement in the total solubility of codrug 9 under the specified conditions with a concentration of 1.8 mM, whereas the solubilities of Cpt and CA4 were 5 μM and 17.2 μM respectively. This enhancement of solubility could be related to the introduced hydrophilic chains that connect between the two anticancer drugs. More interestingly, as the synthesized codrug 9 consists of hydrophobic molecules and hydrophilic chains (amphiphilic structure), this organized structure can self-assembly into diverse supramolecular structure. Moreover, the 1,2,3-tetrazole group has the potential to enhance the construction of various supramolecular systems as the triazole rings facilitate the π–π interactions and has a polarized C–H bond, which could be used as a H-bond donor.\textsuperscript{31,41,42} In this direction, we studied the capability of our compound to self-assemble into micelle structure through atomic force microscopy (AFM) and dynamic light scattering (DLS). The image of AFM resembles the formation of micelle supramolecular structure with a spherical shape as shown in Fig. 1A. In addition, the DLS results showed good dispersibility with a PDI of 0.2 and a hydrodynamic diameter of 146 nm as shown in Fig. 1B. This diameter range is optimum to permit a preferential internalization to cancer cells over the normal cells as previously reported.\textsuperscript{43,44} Moreover, the CMC was estimated using pyrene as a fluorescent probe.\textsuperscript{31} As the concentration of the compound 9 increased, a red shift of pyrene absorbance was noticed in the excitation spectrum (Fig. 1C). In particular, the absorbance band of pyrene in water was at 333 nm, and it shifted to 336 nm when pyrene was embedded in micelles as the pyrene transfer from the water environment to the hydrophobic core of the micelle. Fig. 1C shows the plot of the intensity ratio $I_{336}/I_{333}$ versus concentration. The CMC value was measured to be $1 \times 10^{-3}$ mg ml$^{-1}$ (0.9 mM) as the intersection of the two tangent lines. This value is considered thermodynamically stable enough as a drug delivery vehicle.\textsuperscript{45}

A stability study was also conducted for one week on the synthesized codrug 9 at three various pHs (4.5, 7.4 and 9.2). The percentage of conversion of the co-drug to their parent drugs were measured for one week based on the prepared calibration curves. The obtain results indicated that the synthesized codrug 9 is totally stable at pH 7.4 during the whole week as shown in Fig. 1D. Regarding pH 4.5, a hydrolysis was observed with 20% of the sample after 24 h and maintained this percentage during the whole week. In the case of pH 9.2, a higher hydrolysis was observed with 50% after 24 h and also maintained this percentage during the whole week as shown in Fig. 2A.

Moreover, the complete hydrolysis of the co-drug was also studied in the presence of esterase enzyme. An incubation study was conducted with porcine liver esterase. It was observed a complete hydrolysis of the co-drug after 50 min of incubation with esterase enzyme, which confirms the total conversion of the co-drug to the two active anticancer drugs after 50 min as shown in Fig. 2B.

3.3. MTS study

The cytotoxicity of codrug 9 was investigated on HeLa cells and was compared with the free CA4 and Cpt alone. The effect of

![Fig. 1](image-url)  (A) AFM image; (B) DLS result; (C) CMC result of codrug 9 and (D) vial photograph demonstrates the stability of codrug 9 after 1 week.

![Fig. 2](image-url)  (A) Percentage of hydrolysis at different pHs. (B) Percentage of hydrolysis in the presence of esterase enzyme.

![Fig. 3](image-url)  % Viability of HeLa cancer cells and 3T3 fibroblasts determined by MTS assay after 48 h of treatment. $^* p \leq 0.05$ compared to 0 nM, $^\dagger p \leq 0.05$ compared to corresponding CA4 concentration, $^\ddagger p \leq 0.05$ compared to corresponding CPT concentration, $N = 3$.\textsuperscript{44}
Codrug 9 was also investigated on the noncancerous 3T3 fibroblasts. The MTS assay was implemented in order to objectively estimate the cell viability under various concentrations over 48 h treatment interval, which was the minimal time period required for the drug to affect the cells as shown in Fig. 3. The results demonstrated a concentration dependent cytotoxic activity on HeLa cells under all tested concentrations. Interestingly, there was a clear significant improvement in the anticancer activity of the codrug 9 in comparison to the free drugs over the used concentration range which was up to approximately five folds, which might be attributed to a synergistic activity for the combined drugs as they work in two different modes of actions, which allowed a concentration as low as 23.75 nM to exhibit a strong cytotoxic effect. Moreover, the synergistic effect was confirmed by calculating the combination index (CI) values at different lethal doses (LD$_{50}$, LD$_{75}$, LD$_{90}$, LD$_{95}$) using CompuSyn software developed by Chou and Martin.$^{46}$ As shown in Table 1, a very low LD$_{50}$ of the developed codrug 9 (0.29 nM) was obtained in comparison to the CA4 and Cpt with LD$_{50}$ of 58.3 nM and 50.9 nM, respectively. More interestingly, the CI values at all doses were less than 0.1 which confirm a synergistic effect of the developed co-drug 9. This synergistic activity not only enhances the therapeutic activity but also allows the use of lower doses as confirmed by the calculated dose reduction index (DRI) of each drug as shown in Table 1, which would be expected to decrease the associated side effects. This synergistic effect coincide with the previously reported results of the conjugation of camptothecin and cytarabine through disulfide linkage that showed a rapid cellular uptake with a synergistic anticancer activity in vitro and in vivo studies.$^{47}$ Importantly, there was no significant cytotoxic activity with 3T3 fibroblasts, which might reflect a preferential activity against cancerous cells.

### 3.4. Cellular uptake study of FITC loaded micelles

Cellular uptake of the formed micelles into the cancerous cells is an essential step to have an effective anticancer activity. Since Camptothecin and Combretastatin A4 have low fluorescent intensity, FITC was encapsulated in the self-assembled micelles to obtain a better visualization of the internalization.$^{48}$ The cellular uptake was investigated by inverted fluorescent microscope. Fig. 4 demonstrated the obtained results after the treatment of HeLa cells with FITC loaded micelles at two time intervals (1 h and 2 h). As shown in the Fig. 4, a bright green fluorescence was detected inside the HeLa cells, which indicates an effective and rapid internalization of the developed micelles. Together these findings indicate that the developed micelles have an effective cytotoxicity with rapid internalization by HeLa cancer cells and a good cytocompatibility on 3T3 non-cancerous cells.

### 4. Conclusions

In conclusion, codrug 9 was successfully synthesized with a strategy to improve the water solubility of the used anticancer drugs (CA4 and Cpt). The obtained amphiphilic structure has the capability to self-assemble into micelle structure as confirmed by AFM, DLS and CMC determination. The synthesized codrug 9 showed a good stability at the physiological pH, but could completely hydrolyze into the parent drugs in the presence of an esterase enzyme. The MTS study showed a great improvement in the anticancer activity with a strong synergistic effect as confirmed by the calculated CI without cytotoxic effect on 3T3 normal cells. Moreover, the cellular uptake study showed a rapid internalization of the developed micelles within 1 h of the treatment. The developed codrug 9 could provide a novel therapy for cancer and we recommend further in vivo studies to determine the pharmacokinetic behaviour and the anticancer activity in vivo.

### Conflicts of interest

There are no conflicts to declare.
Acknowledgements

This work was supported by the deanship of Scientific Research at An Najah National University under fund identification number ANNU-1718-Sc-001. We acknowledge Dr Mohammad Qneibi and Ms Shoroqob Sobuh for facilitating cell imaging in their lab.

Notes and references

1 R. L. Siegel, K. D. Miller and A. Jemal, *Ca-A Cancer Journal for Clinicians*, 2018, 68, 7–30.
2 B. Sumer and J. Gao, *Nanomedicine*, 2008, 3, 137–140.
3 L. Y. Ramírez, S. E. Huestis, T. Y. Yap, S. Zyzanski, D. Drotar and E. Kodish, *Pediatr. Blood Cancer*, 2009, 52, 497–502.
4 A. K. Ganti, A. Pearce, M. Haas, R. Viney, S.-A. Pearson, P. Haywood, C. Brown and R. Ward, *PloS One*, 2017, 12, e0184360.
5 M. A. Raji, *Lancet Oncol.*, 2005, 6, 357.
6 R. Iaccovelli, F. Pietrantonio, C. Maggi, F. de Braud and M. Di Bartolomeo, *Crit. Rev. Oncol. Hematol.*, 2016, 98, 24–28.
7 G. Tomasello, M. Ghidini, S. Barni, R. Passalaqua and F. Petrelli, *Expert Rev. Clin. Pharmacol.*, 2017, 10, 649–660.
8 P. Parhi, C. Mohanty and S. K. Sahoo, *Drug Discovery Today*, 2012, 17, 1044–1052.
9 J. A. Kemp, M. S. Shim, C. Y. Heo and Y. J. Kwon, *Adv. Drug Delivery Rev.*, 2016, 98, 3–18.
10 M. Assali, R. Shawahtina, S. Dayeh, M. Shareef and I.-A. Allhmony, *Eur. J. Pharm. Sci.*, 2018, 122, 179–184.
11 S. Saha, M. Ghosh and S. K. Dutta, *RSC Adv.*, 2017, 7, 53322–53333.
12 X. Zhang, Y. Liu, Y. J. Kim, J. Mac, R. Zhuang and P. Wang, *RSC Adv.*, 2017, 7, 19685–19693.
13 V. Abbot, P. Sharma, S. Dhiman, M. N. Noolvi, H. M. Patel and V. Bhardwaj, *RSC Adv.*, 2017, 7, 28313–28349.
14 G. M. Tozer, C. Kanthou, C. S. Parkins and S. A. Hill, *Int. J. Exp. Pathol.*, 2002, 83, 21–38.
15 G. M. Tozer, C. Kanthou and B. C. Baguley, *Nat. Rev. Cancer*, 2005, 5, 423–435.
16 P. Hinnen and F. A. L. M. Eskens, *Br. J. Cancer*, 2007, 96, 1159–1165.
17 R. Dorr, K. Dvorakova, K. Sneed, D. Alberts, S. Salmon and G. R. Pettit, *Invest. New Drugs*, 1996, 14, 131–137.
18 G. J. Rustin, S. M. Galbraith, H. Anderson, M. Stratford, L. K. Folkes, L. Sena, L. Gumbrell and P. M. Price, *J. Clin. Oncol.*, 2003, 21, 2815–2822.
19 N. H. Oberlies and D. J. Kroll, *J. Nat. Prod.*, 2004, 67, 129–135.
20 L. P. Rivory and J. Robert, *Pharmacol. Ther.*, 1995, 68, 269–296.
21 M. Assali, J. J. Cid, M. Pernia-Leal, M. Munoz-Bravo, I. Fernandez, R. E. Wellinger and N. Khair, *ACS Nano*, 2013, 7, 2145–2153.
22 S. Sheng, Y. Chen, T. Zhang, M. Ding, Y. Wu, Z. Shen, G. Han and X. Wang, *RSC Adv.*, 2017, 7, 46370–46377.
23 L. Bentzen, S. Keiding, M. R. Horsman, T. Grönroos, S. B. Hansen and J. Overgaard, *Acta Oncol.*, 2009, 41, 304–312.
24 R. F. Kallman, G. L. DeNardo and M. J. Stasch, *Cancer Res.*, 1972, 32, 483–490.
25 R. P. Hill, *Br. J. Cancer, Suppl.*, 1980, 4, 230–239.
26 R. K. Jain, *Cancer Res.*, 1987, 47, 3039–3051.
27 D. W. Siemann, D. J. Chaplin and M. R. Horsman, *Cancer Invest.*, 2017, 35, 519–534.
28 H. Liu, Y. Xie, Y. Zhang, Y. Cai, B. Li, H. Mao and R. Yu, *RSC Adv.*, 2016, 6, 113933–113939.
29 I. Horcas, R. Fernández, J. M. Gómez-Rodriguez, J. Colchero, J. Gómez-Herrero and A. M. Baro, *Rev. Sci. Instrum.*, 2007, 78, 013705.
30 M. Assali, M. Joulani, R. Awwad, M. Assad, M. Almasri, N. Kitanna and A. N. Zaid, *ChemistrySelect*, 2016, 1, 1132–1135.
31 M. Wilhelm, C. L. Zhao, Y. Wang, R. Xu, M. A. Winnik, J. L. Mura, G. Riess and M. D. Croucher, *Macromolecules*, 1991, 24, 1033–1040.
32 M. Assali, A. N. Zaid, F. Abdallah, M. Almasri and R. Khayyat, *Int. J. Nanomed.*, 2017, 12, 6647–6659.
33 T. C. Chou and P. Talalay, *Adv. Enzyme Regul.*, 1984, 22, 27–55.
34 Y. Guo, P. Zhang, Q. Zhao, K. Wang and Y. Luan, *Macromol. Biosci.*, 2016, 16, 420–431.
35 P. Zhang, W. He, H. Zhang, C. Huang, D. Zhao and Y. Luan, *ChemPlusChem*, 2016, 81, 1237–1244.
36 H. C. Kolb and K. B. Sharpless, *Drug Discovery Today*, 2003, 8, 1128–1137.
37 H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, 40, 2004–2021.
38 J. Sheng, N. Ma, Y. Wang, W.-C. Ye and B.-X. Zhao, *Drug Des., Dev. Ther.*, 2015, 2015, 1585–1599.
39 M. P. Mathew, E. Tan, S. Shah, R. Bhattacharya, M. Adam Meledeo, J. Huang, F. A. Espinoza and K. J. Yaremos, *Bioorg. Med. Chem. Lett.*, 2012, 22, 6929–6933.
40 C. A. Mcdonald, Y.-L. Jiang, M. Brannon, K. Krishnan and W. L. Stone, *BMC Cancer*, 2014, 14, 1–13.
41 L. Xu, Y. Li and Y. Li, *Asian J. Org. Chem.*, 2014, 3, 582–602.
42 B. Schulze and U. S. Schubert, *Chem. Soc. Rev.*, 2014, 43, 2522.
43 M. P. Desai, V. Labhasetwar, E. Walter, R. J. Levy and G. L. Amidon, *Pharm. Res.*, 1997, 14, 1568–1573.
44 A. Prokop and J. M. Davidson, *J. Pharm. Sci.*, 2008, 97, 3518–3590.
45 W. Xu, P. Ling and T. Zhang, *J. Drug Delivery*, 2013, 2013, 1–15.
46 T. C. Chou, *Pharmacol. Rev.*, 2006, 58, 621–681.
47 W. He, X. Hu, W. Jiang, R. Liu, D. Zhang, J. Zhang, Z. Li and Y. Luan, *Adv. Healthcare Mater.*, 2017, 6, 1700829.
48 W.-M. Li, D.-M. Liu and S.-Y. Chen, *J. Mater. Chem.*, 2011, 21, 12381–12388.